Inspire Medical Systems, Inc. (INSP)

Option volume on INSP indicates large block hedging by prime desks. Downside asymmetry is expanding.

On our desk, INSP is presenting a classic high-stakes puzzle following its recent 28% monthly rally and Q2 earnings beat. Management raised full-year 2026 guidance to a range of $835 million to $875 million, which initially surprised the Street given that Q2 revenue actually contracted 7.6% year-over-year to $200.6 million due to stubborn coding and reimbursement headwinds. With short interest hovering near 19.8% and an average consensus price target of $83 against a wide dispersion from $39 to $255, the valuation trade-off is intense. We are tracking whether the margin expansion from the Inspire V system mix and disciplined operating cuts via Project Horizon can genuinely offset persistent top-line volume pressure before initiating a heavy long position.

In our clinic, implementing the Inspire therapy platform continues to face friction on the ground. While over 1,500 physicians actively perform implants and more than 140,000 patients have received the device, recent coding updates, prior-authorization bottlenecks, and uneven Medicare reimbursement policies have directly slowed down our scheduling throughput. Management noted these disruptions wiped out roughly $40 million in procedure volumes during the second quarter alone. Even though newer iterations like the Inspire V system showcase strong clinical data and drive better gross margins for the company, clinical adoption timelines remain handcuffed by administrative hurdles and external authorization delays that have yet to be fully resolved.

Watching the macro risk profile for INSP, the core vulnerability lies in the disconnect between long-term market opportunity and near-term operational friction. The company estimates a U.S. obstructive sleep apnea market opportunity exceeding $10 billion with penetration under 5%, which sounds incredible on paper. However, execution is currently being bogged down by reimbursement uncertainties and intensifying competitive pressures. Even with a sturdy balance sheet boasting $415 million in cash and investments with zero debt, the projected net losses and cautious multi-quarter visibility imply that patient capital is required. We view the current risk-reward balance as heavily dependent on whether management can successfully navigate the ongoing CPT code transitions and secure stable reimbursement pathways.